Daxor Corp. gained 56% on Wednesday, following new data from its study showing that patient care individualized by its Precision Blood Volume Analysis (BVA) reduces heart failure readmissions by 56% and mortality by over 80%.
from RTT - Biotech http://ift.tt/2FRhXOb
via IFTTT
No comments:
Post a Comment